|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.33 - 2.64|
|52 Week Range||0.06 - 3.69|
|PE Ratio (TTM)||-1.47|
|Earnings Date||Aug 8, 2017 - Aug 14, 2017|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||75.00|
NEW YORK, NY / ACCESSWIRE / August 15, 2017 / It was a big trading day for both Marinus Pharmaceuticals and CEL-SCI Corporation on Monday. CEL-SCI shares were on the rampage to a new high after the FDA ...
The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.
CEL-SCI Corporation today announced it has received a letter from the U.S. Food and Drug Administration stating that the clinical hold that had been imposed on the Company’s Phase 3 cancer study with Multikine* has been removed and that all clinical trial activities under this Investigational New Drug application may resume.